Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review
Research output: Contribution to journal › Article
Colleges, School and Institutes
Previous research suggests uncertainty whether or not there is any additional benefit in adding antiplatelet therapy (APT) to anticoagulation therapy (ACT) in patients with high-risk atrial fibrillation (AF) in terms of reduction in vascular events, including stroke. The existing guidelines acknowledge an increased risk of bleeding associated with such a strategy; however, there is no consensus on the treatment pathway.
|Number of pages||188|
|Journal||Health Technology Assessment|
|Publication status||Published - Jul 2013|